ADMA Biologics, Inc.
NASDAQ:ADMABiotechnology
Healthcare
$13.34 +0.42%
+$0.04 today
- Market cap
- $2.96B
- Beta
- 0.73
- P/E (TTM)
- 12.1
- EPS (TTM)
- $0.70
52W Low $7.21High $20.46
Volume 3.62M
Average 7.07M
Income Statement
Follow revenue through to earnings.
Revenue
$510.17M
FY 2025 · Annual
+19.6% YoYOperating Income
$191.44M
FY 2025 · Annual
+37.7% YoYNet Income
$146.93M
FY 2025 · Annual
-25.7% YoYIncome Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 80.94M | 154.08M | 258.22M | 426.45M | 510.17M |
| Cost of Revenue | 79.77M | 118.82M | 169.27M | 206.9M | 217.41M |
| Gross Profit | 1.17M | 35.27M | 88.94M | 219.55M | 292.77M |
| Gross Margin | 1.4% | 22.9% | 34.4% | 51.5% | 57.4% |
| Research & Development | 3.65M | 3.61M | 3.3M | 1.81M | 4.76M |
| Selling, General & Admin | 42.9M | 52.46M | 59.02M | 74.12M | 91.58M |
| Operating Expenses | 59.55M | 74.63M | 67.31M | 80.57M | 101.32M |
| Depreciation & Amortization | 5.5M | 7.11M | 8.33M | 8.05M | 8.1M |
| EBITDA | (53.1M) | (39.51M) | 5.12M | 147.69M | 197.86M |
| EBITDA Margin | -65.6% | -25.6% | 2.0% | 34.6% | 38.8% |
| Operating Income | (58.37M) | (39.37M) | 21.63M | 138.98M | 191.44M |
| Operating Margin | -72.1% | -25.5% | 8.4% | 32.6% | 37.5% |
| Interest Income | 34.53K | 44.83K | 1.62M | 2.1M | 1.87M |
| Interest Expense | 13.06M | 19.28M | 25.03M | 13.93M | 7.11M |
| Other Income / Expenses | (13.27M) | (26.54M) | (49.87M) | (13.27M) | (8.79M) |
| Income Before Tax | (71.65M) | (65.9M) | (28.24M) | 125.71M | 182.66M |
| Pre-Tax Margin | -88.5% | -42.8% | -10.9% | 29.5% | 35.8% |
| Income Tax Expense | 0 | 0 | 0 | (71.96M) | 35.73M |
| Net Income | (71.65M) | (65.9M) | (28.24M) | 197.67M | 146.93M |
| Net Margin | -88.5% | -42.8% | -10.9% | 46.4% | 28.8% |
| EPS (Basic) | (0.61) | (0.43) | (0.13) | 0.85 | 0.62 |
| EPS (Diluted) | (0.61) | (0.43) | (0.13) | 0.81 | 0.60 |
| 139.58M | 197.87M | 223.98M | 233.08M | 238.3M | |
| 139.58M | 197.87M | 223.98M | 243.34M | 244.9M |
ADMA Earnings Waterfall · TTM
NASDAQ:ADMA · Revenue to Net Income
Key Ratios
EPS$0.70
Gross Margin65.0%
Net Margin33.2%
P/E Ratio17.6
P/S Ratio22.8
Analysis
$512.3M of revenue converted into $169.0M of net income for the selected period. Gross margin is 65.0% and net margin is 33.2%, showing how much revenue survives after costs and taxes. EPS is $0.70, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Nov 4, 2026 | |
| SC 13G | SC 13G filing | Aug 7, 2026 |
How much revenue does ADMA generate?
ADMA Biologics, Inc. (ADMA) reported $510.17M of revenue in fiscal 2025.
Is ADMA profitable?
ADMA Biologics, Inc. (ADMA) reported $146.93M of net income, with a net margin of 28.8%.
Continue the stock analysis
Jump to another research area for this company.